Steps for Building Supply Chain Integrity and Resilience in Europe
Speakers from the European Fine Chemicals Group, the voice of fine chemical manufacturers in Europe, led a discussion on the ‘globalised, fragmented and complex’ API and raw materials supply chain, in this month’s edition of the CPHI Webinar Series.
Gildas Barreyre, General Secretary at Seqens and Dirkjan van Zoelen, Manager Development and Technical Support at Aspen Oss B.V, both representing the EFCG, shared the historical background of global API production, sharing that in the year 2000, Europe held a strong position as a global API producer with 53% of CEP manufacturers worldwide.
Fast forward to 2020, and this figure drops to 33%, with the majority of manufacturers (59%) now located in Asia – a shift driven by the potential for high volume, low margin production. Investment and operating costs for active ingredients are estimated to be 20-40% lower in Asia.
While price and volume might offer distinct advantages, such reliance on Asian manufacturers does lead to a number of vulnerabilities in the supply chain for APIs and raw materials in Europe. An IQVIA study conducted for the EFCG estimates overall EU dependency on Asia to be 74%, of which 70% is upon China.
The EFCG shared these concerns with the EU commission pre-pandemic about the dependence upon Asian manufacturers for Europe’s needs, and is working towards a more ‘robust, sustainable and competitive’ infrastructure for the production of APIs, raw materials, and intermediates, highlighting a few key areas which expose vulnerability in the EU supply chain:
1. Scarcity of Technology
Some of the key technologies required to manufacture a multitude of APIs are now either scarce or completely unavailable within Europe – this includes nitration, fermentation, chlorination, and fluorination.
As an example, only 27% of European manufacturers are currently able to use nitration technology – despite the fact that 65% of API production routes require this capability.
Source: IQVIA
2. Quality Control
While cost and volume have long been an advantage of manufacturing APIs in Asia, concerns over product quality have led to plant shutdowns, which in turn creates shortage of supply.
Steps have been taken to mitigate quality concerns, for example the creation of working groups, like that between China’s NMPA and the European Commission’s DG Sante, to identify training needs in the API space and enforce GMP standards. Regardless, van Zoelen says local government’s act swiftly when concerns arise, and if you are dependent on non-compliant supplier for a specific molecule, this is highly disruptive.
3. Supplier Consolidation
Where suppliers consolidate and the end result is one or two major players who take the lead in meeting global demand, a vulnerability is created in the supply chain. As we saw with COVID, if those who have the monopoly on production are not able to meet demand due to logistical challenges or disruption, this has serious consequences for those regions relying on consistent supply of raw materials and APIs.
The presenters shared examples from numerous studies which have identified Europe’s dependence on Asian suppliers as the main cause of vulnerability, such as the ProGenerika study (Sept. 20) commissioned by German generics producers, which traced the EU's heavy dependence on 22 critical active ingredients, and the IQVIA study1 (Jan. 21) commissioned by the EFCG on the root causes of vulnerabilities in the medicines chain.
Steps for a more robust and resilient European supply chain
How can these vulnerabilities be addressed for long-term supply chain security and resilience in Europe? The speakers outline three measures which the EFCG is working towards, to build more competitive manufacturing capabilities in Europe, and to level the playing field between European and Asian producers.
1. Supporting an innovative, competitive and sustainable European offer - Building a dynamic, competitive and innovative pharmaceutical industry ecosystem by supporting the reshoring of critical technologies and strengthening local manufacturing capabilities.
2. Promote sustainable production in public tenders and price policies - Integrate criteria such as security of supply and environmental policies into supplier selection criteria, and reform pricing policies and reimbursement mechanisms in Europe.
3. Financing innovation along the value chain for greener and more efficient manufacturing processes – Supporting innovation across the entire value chain for more sustainable and efficient manufacturing processes – a key differentiator between European and Asian production, and maintaining and developing the EU skills and knowledge base.
The full webinar is now available to access on-demand, for free. Click here to watch.
Related News
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile... -
News Eli Lilly eyes India as next global export hub
Eli Lilly and Co. is positioning India as a key player in its global supply chain, driven by the booming success of its diabetes and obesity drug, Mounjaro.
-
News Women in Pharma: Quality leadership, quality services
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News WuXi Biologics accomplishes automated continuous drug substance production at pilot-scale
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale.
-
News Women in Pharma: A Place to Share Worries and Challenges - CPHI Women in CPHI Japan
This year’s CPHI Women event was held on 10 April 2025 inside the CPHI Japan venue adjacent to Tokyo Big Sight. Now in its 9th edition, CPHI Women aims to foster networking opportunities for women working in the pharmaceutical industry in Japan. -
News EU Commission to restrict Chinese companies in medical devices procurement
The European Commission, the primary executive arm of the EU, announced their decision to exclude Chinese companies from EU government purchases of medical devices exceeding EUR€5 million in a bid to rebalance trade barriers.